|
|
| About the manufacturer of
Ranitidine – Zantac |
Actavis is among the world's leading standard pharmaceutical
companies Actavis is wholly and solely working to expertise in the
development, manufacture and sale of generic pharmaceuticals like
Ranitidine - Zantac. Headquarter is in Iceland, the company has wide
business in over 40 countries, with 12,000 employees. The company's
market yearly sale is approximately EUR3.1bn (US$4 billion) and is
also been listed in the Iceland Stock Exchange. Actavis is expecting
total sale of EUR1.8bn in year 2007, with about one-third of the
sales is coming from the United States only where it developed
Ranitidine - Zantac, which is the largest market of the company. In
the US alone, the company made 37 ANDA filings in 2006 and expected
to be 40-45 in the year 2008 along with 19-20 new product launching.
The company's US office is in New Jersey, Maryland and North
Carolina. The registered site for the company is http://www.actavis.com/.
Company has given some information in this press release contains
many visionary statements with respect to the financial state,
outcome of operations and businesses of Actavis. By the nature,
these positive signs and forecasts involve risk and uncertainty
because it is relate to events and depend on situation that will
happen in the future. There are a number of aspects that could
influence genuine results and developments to vary substantially
from that articulated or disguised by these futurist statements.
This company work with discipline and has maintained over the time
fluctuation of exchange rate. It never compromise on the research
and development of new products which is shown in the success of
Ranitidine - Zantac and left no place for any hindrance in achieve
commercial success, it has always played fair in competition, price
and price lessening.
|
|
